Loading…

Does surgical technique influence outcomes after simultaneous kidney–pancreas transplantation?

Since 1995, many centers have switched from bladder to enteric drainage of the exocrine secretions in simultaneous kidney–pancreas transplantation (SKPT). Enteric exocrine drainage may be performed with either systemic (systemic-enteric [S-E]) or portal (portal-enteric [P-E]) venous delivery of insu...

Full description

Saved in:
Bibliographic Details
Published in:Transplantation proceedings 2004-05, Vol.36 (4), p.1076-1077
Main Authors: Stratta, R.J, Alloway, R.R, Lo, A, Hodge, E.E
Format: Article
Language:English
Subjects:
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c406t-66727c24793fdaa06206667cabac3a170330516f8bd95bceba46ed16ed3c5d123
cites cdi_FETCH-LOGICAL-c406t-66727c24793fdaa06206667cabac3a170330516f8bd95bceba46ed16ed3c5d123
container_end_page 1077
container_issue 4
container_start_page 1076
container_title Transplantation proceedings
container_volume 36
creator Stratta, R.J
Alloway, R.R
Lo, A
Hodge, E.E
description Since 1995, many centers have switched from bladder to enteric drainage of the exocrine secretions in simultaneous kidney–pancreas transplantation (SKPT). Enteric exocrine drainage may be performed with either systemic (systemic-enteric [S-E]) or portal (portal-enteric [P-E]) venous delivery of insulin. Controversy exists regarding the optimal surgical technique. From March 1999 to May 2001, a total of 297 SKPT patients were enrolled into a prospective, multicenter, randomized, open-label, comparative trial of two daclizumab dosing strategies versus no-antibody induction in combination with tacrolimus, mycophenolate mofetil, and steroids in SKPT recipients. Surgical techniques were center specific. A total of 171 patients (58%) underwent SKPT with S-E drainage, 96 (32%) with P-E drainage, and 30 (10%) with systemic-bladder (S-B) drainage. The two groups randomized to daclizumab induction were similar with regard to surgical technique (64% S-E, 25% P-E, 11% S-B drainage). Demographic and transplant characteristics and immunosuppression were similar among the three groups, except that more patients with P-E drainage did not receive antibody induction. At 6 months, no differences were seen in patient and graft survival rates, surgical complications including pancreas thrombosis, rates of rejection or infection, readmissions, and kidney and pancreas allograft function among the three different surgical techniques. The 6-month results of this multicenter study suggest no significant differences in outcomes in SKPT recipients according to surgical technique.
doi_str_mv 10.1016/j.transproceed.2004.04.051
format article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_72016865</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0041134504004841</els_id><sourcerecordid>72016865</sourcerecordid><originalsourceid>FETCH-LOGICAL-c406t-66727c24793fdaa06206667cabac3a170330516f8bd95bceba46ed16ed3c5d123</originalsourceid><addsrcrecordid>eNqNkM1u1DAQgC0EotvCK6AICW5Z_JM4u1xQ1ZYfqRIXOJvJZAJeEmexHaTeeAfekCdhoqxQj0hjWfZ8Mx5_QjxXcquksq8O2xwhpGOckKjbaimr7RK1eiA2ateYUlttHooNJ1SpTFWfifOUDpLPujKPxZmq1b4yjdmIL9cTpSLN8atHGIpM-C34HzMVPvTDTAGpmOaM08gU9Jlikfw4DxkCTXMqvvsu0N2fX7-PEDASpGIdbYCQIfspvHkiHvUwJHp62i_E57c3n67el7cf3324urwtsZI2l9Y2ukFdNXvTdwDSamn5DqEFNKAaaQz_z_a7ttvXLVILlaVO8TJYd0qbC_Fy7ctaeP6U3egT0jCsk7pGs7qdrRl8vYIYp5Qi9e4Y_QjxzinpFr_u4O77dYtft0StuPjZ6ZW5HTn3r_QklIEXJwASC-25Efp0j9s10u4lc9crR-zkp6foEvpFd-cjYXbd5P9nnr8CHaO8</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>72016865</pqid></control><display><type>article</type><title>Does surgical technique influence outcomes after simultaneous kidney–pancreas transplantation?</title><source>Elsevier</source><creator>Stratta, R.J ; Alloway, R.R ; Lo, A ; Hodge, E.E</creator><creatorcontrib>Stratta, R.J ; Alloway, R.R ; Lo, A ; Hodge, E.E ; for the PIVOT Study Group ; PIVOT Study Group</creatorcontrib><description>Since 1995, many centers have switched from bladder to enteric drainage of the exocrine secretions in simultaneous kidney–pancreas transplantation (SKPT). Enteric exocrine drainage may be performed with either systemic (systemic-enteric [S-E]) or portal (portal-enteric [P-E]) venous delivery of insulin. Controversy exists regarding the optimal surgical technique. From March 1999 to May 2001, a total of 297 SKPT patients were enrolled into a prospective, multicenter, randomized, open-label, comparative trial of two daclizumab dosing strategies versus no-antibody induction in combination with tacrolimus, mycophenolate mofetil, and steroids in SKPT recipients. Surgical techniques were center specific. A total of 171 patients (58%) underwent SKPT with S-E drainage, 96 (32%) with P-E drainage, and 30 (10%) with systemic-bladder (S-B) drainage. The two groups randomized to daclizumab induction were similar with regard to surgical technique (64% S-E, 25% P-E, 11% S-B drainage). Demographic and transplant characteristics and immunosuppression were similar among the three groups, except that more patients with P-E drainage did not receive antibody induction. At 6 months, no differences were seen in patient and graft survival rates, surgical complications including pancreas thrombosis, rates of rejection or infection, readmissions, and kidney and pancreas allograft function among the three different surgical techniques. The 6-month results of this multicenter study suggest no significant differences in outcomes in SKPT recipients according to surgical technique.</description><identifier>ISSN: 0041-1345</identifier><identifier>EISSN: 1873-2623</identifier><identifier>DOI: 10.1016/j.transproceed.2004.04.051</identifier><identifier>PMID: 15194373</identifier><identifier>CODEN: TRPPA8</identifier><language>eng</language><publisher>New York, NY: Elsevier Inc</publisher><subject>Antibodies, Monoclonal - therapeutic use ; Antibodies, Monoclonal, Humanized ; Biological and medical sciences ; Graft Rejection - epidemiology ; Graft Survival ; Humans ; Immunoglobulin G - therapeutic use ; Immunosuppressive Agents - therapeutic use ; Kidney Function Tests ; Kidney Transplantation - immunology ; Kidney Transplantation - methods ; Kidney Transplantation - mortality ; Medical sciences ; Mycophenolic Acid - analogs &amp; derivatives ; Mycophenolic Acid - therapeutic use ; Pancreas Transplantation - immunology ; Pancreas Transplantation - methods ; Pancreas Transplantation - mortality ; Surgery (general aspects). Transplantations, organ and tissue grafts. Graft diseases ; Surgery of the urinary system ; Survival Analysis ; Survivors ; Tacrolimus - therapeutic use ; Treatment Outcome</subject><ispartof>Transplantation proceedings, 2004-05, Vol.36 (4), p.1076-1077</ispartof><rights>2004 Elsevier Inc.</rights><rights>2004 INIST-CNRS</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c406t-66727c24793fdaa06206667cabac3a170330516f8bd95bceba46ed16ed3c5d123</citedby><cites>FETCH-LOGICAL-c406t-66727c24793fdaa06206667cabac3a170330516f8bd95bceba46ed16ed3c5d123</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>309,310,314,780,784,789,790,23930,23931,25140,27924,27925</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&amp;idt=15870690$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/15194373$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Stratta, R.J</creatorcontrib><creatorcontrib>Alloway, R.R</creatorcontrib><creatorcontrib>Lo, A</creatorcontrib><creatorcontrib>Hodge, E.E</creatorcontrib><creatorcontrib>for the PIVOT Study Group</creatorcontrib><creatorcontrib>PIVOT Study Group</creatorcontrib><title>Does surgical technique influence outcomes after simultaneous kidney–pancreas transplantation?</title><title>Transplantation proceedings</title><addtitle>Transplant Proc</addtitle><description>Since 1995, many centers have switched from bladder to enteric drainage of the exocrine secretions in simultaneous kidney–pancreas transplantation (SKPT). Enteric exocrine drainage may be performed with either systemic (systemic-enteric [S-E]) or portal (portal-enteric [P-E]) venous delivery of insulin. Controversy exists regarding the optimal surgical technique. From March 1999 to May 2001, a total of 297 SKPT patients were enrolled into a prospective, multicenter, randomized, open-label, comparative trial of two daclizumab dosing strategies versus no-antibody induction in combination with tacrolimus, mycophenolate mofetil, and steroids in SKPT recipients. Surgical techniques were center specific. A total of 171 patients (58%) underwent SKPT with S-E drainage, 96 (32%) with P-E drainage, and 30 (10%) with systemic-bladder (S-B) drainage. The two groups randomized to daclizumab induction were similar with regard to surgical technique (64% S-E, 25% P-E, 11% S-B drainage). Demographic and transplant characteristics and immunosuppression were similar among the three groups, except that more patients with P-E drainage did not receive antibody induction. At 6 months, no differences were seen in patient and graft survival rates, surgical complications including pancreas thrombosis, rates of rejection or infection, readmissions, and kidney and pancreas allograft function among the three different surgical techniques. The 6-month results of this multicenter study suggest no significant differences in outcomes in SKPT recipients according to surgical technique.</description><subject>Antibodies, Monoclonal - therapeutic use</subject><subject>Antibodies, Monoclonal, Humanized</subject><subject>Biological and medical sciences</subject><subject>Graft Rejection - epidemiology</subject><subject>Graft Survival</subject><subject>Humans</subject><subject>Immunoglobulin G - therapeutic use</subject><subject>Immunosuppressive Agents - therapeutic use</subject><subject>Kidney Function Tests</subject><subject>Kidney Transplantation - immunology</subject><subject>Kidney Transplantation - methods</subject><subject>Kidney Transplantation - mortality</subject><subject>Medical sciences</subject><subject>Mycophenolic Acid - analogs &amp; derivatives</subject><subject>Mycophenolic Acid - therapeutic use</subject><subject>Pancreas Transplantation - immunology</subject><subject>Pancreas Transplantation - methods</subject><subject>Pancreas Transplantation - mortality</subject><subject>Surgery (general aspects). Transplantations, organ and tissue grafts. Graft diseases</subject><subject>Surgery of the urinary system</subject><subject>Survival Analysis</subject><subject>Survivors</subject><subject>Tacrolimus - therapeutic use</subject><subject>Treatment Outcome</subject><issn>0041-1345</issn><issn>1873-2623</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2004</creationdate><recordtype>article</recordtype><recordid>eNqNkM1u1DAQgC0EotvCK6AICW5Z_JM4u1xQ1ZYfqRIXOJvJZAJeEmexHaTeeAfekCdhoqxQj0hjWfZ8Mx5_QjxXcquksq8O2xwhpGOckKjbaimr7RK1eiA2ateYUlttHooNJ1SpTFWfifOUDpLPujKPxZmq1b4yjdmIL9cTpSLN8atHGIpM-C34HzMVPvTDTAGpmOaM08gU9Jlikfw4DxkCTXMqvvsu0N2fX7-PEDASpGIdbYCQIfspvHkiHvUwJHp62i_E57c3n67el7cf3324urwtsZI2l9Y2ukFdNXvTdwDSamn5DqEFNKAaaQz_z_a7ttvXLVILlaVO8TJYd0qbC_Fy7ctaeP6U3egT0jCsk7pGs7qdrRl8vYIYp5Qi9e4Y_QjxzinpFr_u4O77dYtft0StuPjZ6ZW5HTn3r_QklIEXJwASC-25Efp0j9s10u4lc9crR-zkp6foEvpFd-cjYXbd5P9nnr8CHaO8</recordid><startdate>20040501</startdate><enddate>20040501</enddate><creator>Stratta, R.J</creator><creator>Alloway, R.R</creator><creator>Lo, A</creator><creator>Hodge, E.E</creator><general>Elsevier Inc</general><general>Elsevier Science</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20040501</creationdate><title>Does surgical technique influence outcomes after simultaneous kidney–pancreas transplantation?</title><author>Stratta, R.J ; Alloway, R.R ; Lo, A ; Hodge, E.E</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c406t-66727c24793fdaa06206667cabac3a170330516f8bd95bceba46ed16ed3c5d123</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2004</creationdate><topic>Antibodies, Monoclonal - therapeutic use</topic><topic>Antibodies, Monoclonal, Humanized</topic><topic>Biological and medical sciences</topic><topic>Graft Rejection - epidemiology</topic><topic>Graft Survival</topic><topic>Humans</topic><topic>Immunoglobulin G - therapeutic use</topic><topic>Immunosuppressive Agents - therapeutic use</topic><topic>Kidney Function Tests</topic><topic>Kidney Transplantation - immunology</topic><topic>Kidney Transplantation - methods</topic><topic>Kidney Transplantation - mortality</topic><topic>Medical sciences</topic><topic>Mycophenolic Acid - analogs &amp; derivatives</topic><topic>Mycophenolic Acid - therapeutic use</topic><topic>Pancreas Transplantation - immunology</topic><topic>Pancreas Transplantation - methods</topic><topic>Pancreas Transplantation - mortality</topic><topic>Surgery (general aspects). Transplantations, organ and tissue grafts. Graft diseases</topic><topic>Surgery of the urinary system</topic><topic>Survival Analysis</topic><topic>Survivors</topic><topic>Tacrolimus - therapeutic use</topic><topic>Treatment Outcome</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Stratta, R.J</creatorcontrib><creatorcontrib>Alloway, R.R</creatorcontrib><creatorcontrib>Lo, A</creatorcontrib><creatorcontrib>Hodge, E.E</creatorcontrib><creatorcontrib>for the PIVOT Study Group</creatorcontrib><creatorcontrib>PIVOT Study Group</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Transplantation proceedings</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Stratta, R.J</au><au>Alloway, R.R</au><au>Lo, A</au><au>Hodge, E.E</au><aucorp>for the PIVOT Study Group</aucorp><aucorp>PIVOT Study Group</aucorp><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Does surgical technique influence outcomes after simultaneous kidney–pancreas transplantation?</atitle><jtitle>Transplantation proceedings</jtitle><addtitle>Transplant Proc</addtitle><date>2004-05-01</date><risdate>2004</risdate><volume>36</volume><issue>4</issue><spage>1076</spage><epage>1077</epage><pages>1076-1077</pages><issn>0041-1345</issn><eissn>1873-2623</eissn><coden>TRPPA8</coden><abstract>Since 1995, many centers have switched from bladder to enteric drainage of the exocrine secretions in simultaneous kidney–pancreas transplantation (SKPT). Enteric exocrine drainage may be performed with either systemic (systemic-enteric [S-E]) or portal (portal-enteric [P-E]) venous delivery of insulin. Controversy exists regarding the optimal surgical technique. From March 1999 to May 2001, a total of 297 SKPT patients were enrolled into a prospective, multicenter, randomized, open-label, comparative trial of two daclizumab dosing strategies versus no-antibody induction in combination with tacrolimus, mycophenolate mofetil, and steroids in SKPT recipients. Surgical techniques were center specific. A total of 171 patients (58%) underwent SKPT with S-E drainage, 96 (32%) with P-E drainage, and 30 (10%) with systemic-bladder (S-B) drainage. The two groups randomized to daclizumab induction were similar with regard to surgical technique (64% S-E, 25% P-E, 11% S-B drainage). Demographic and transplant characteristics and immunosuppression were similar among the three groups, except that more patients with P-E drainage did not receive antibody induction. At 6 months, no differences were seen in patient and graft survival rates, surgical complications including pancreas thrombosis, rates of rejection or infection, readmissions, and kidney and pancreas allograft function among the three different surgical techniques. The 6-month results of this multicenter study suggest no significant differences in outcomes in SKPT recipients according to surgical technique.</abstract><cop>New York, NY</cop><pub>Elsevier Inc</pub><pmid>15194373</pmid><doi>10.1016/j.transproceed.2004.04.051</doi><tpages>2</tpages></addata></record>
fulltext fulltext
identifier ISSN: 0041-1345
ispartof Transplantation proceedings, 2004-05, Vol.36 (4), p.1076-1077
issn 0041-1345
1873-2623
language eng
recordid cdi_proquest_miscellaneous_72016865
source Elsevier
subjects Antibodies, Monoclonal - therapeutic use
Antibodies, Monoclonal, Humanized
Biological and medical sciences
Graft Rejection - epidemiology
Graft Survival
Humans
Immunoglobulin G - therapeutic use
Immunosuppressive Agents - therapeutic use
Kidney Function Tests
Kidney Transplantation - immunology
Kidney Transplantation - methods
Kidney Transplantation - mortality
Medical sciences
Mycophenolic Acid - analogs & derivatives
Mycophenolic Acid - therapeutic use
Pancreas Transplantation - immunology
Pancreas Transplantation - methods
Pancreas Transplantation - mortality
Surgery (general aspects). Transplantations, organ and tissue grafts. Graft diseases
Surgery of the urinary system
Survival Analysis
Survivors
Tacrolimus - therapeutic use
Treatment Outcome
title Does surgical technique influence outcomes after simultaneous kidney–pancreas transplantation?
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-06T06%3A18%3A16IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Does%20surgical%20technique%20influence%20outcomes%20after%20simultaneous%20kidney%E2%80%93pancreas%20transplantation?&rft.jtitle=Transplantation%20proceedings&rft.au=Stratta,%20R.J&rft.aucorp=for%20the%20PIVOT%20Study%20Group&rft.date=2004-05-01&rft.volume=36&rft.issue=4&rft.spage=1076&rft.epage=1077&rft.pages=1076-1077&rft.issn=0041-1345&rft.eissn=1873-2623&rft.coden=TRPPA8&rft_id=info:doi/10.1016/j.transproceed.2004.04.051&rft_dat=%3Cproquest_cross%3E72016865%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c406t-66727c24793fdaa06206667cabac3a170330516f8bd95bceba46ed16ed3c5d123%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=72016865&rft_id=info:pmid/15194373&rfr_iscdi=true